AI Engines For more Details: Perplexity Kagi Labs You
Gastroesophageal Reflux Disease (GERD): Itopride helps alleviate symptoms of GERD, such as heartburn and acid reflux, by increasing the motility of the gastrointestinal tract and enhancing gastric emptying.
Functional Dyspepsia: Itopride is commonly prescribed for the treatment of functional dyspepsia, a condition characterized by persistent or recurrent pain or discomfort centered in the upper abdomen, often accompanied by bloating, early satiety, and nausea.
Symptomatic Relief of Dyspeptic Symptoms: Itopride can provide relief from dyspeptic symptoms, including postprandial fullness, bloating, nausea, and epigastric pain.
Enhancement of Gastric Motility: Itopride works by blocking the dopamine D2 receptors and acetylcholinesterase, leading to an increase in acetylcholine levels and stimulation of gastrointestinal motility.
Improvement in Gastric Emptying: By enhancing gastric motility, itopride promotes faster emptying of the stomach contents, which can be beneficial for individuals with delayed gastric emptying.
Treatment of Gastroparesis: Itopride may be used off-label in the treatment of gastroparesis, a condition characterized by delayed gastric emptying, resulting in symptoms such as nausea, vomiting, abdominal pain, and bloating.
Reduction of Gastrointestinal Symptoms: Itopride can help reduce symptoms associated with various gastrointestinal disorders, including abdominal discomfort, distension, and early satiety.
Adjunctive Therapy: Itopride may be used as adjunctive therapy alongside proton pump inhibitors (PPIs) or H2-receptor antagonists in the management of GERD or other acid-related disorders.
Minimal Central Nervous System (CNS) Side Effects: Unlike some other gastrointestinal motility agents, itopride has minimal penetration of the blood-brain barrier, reducing the risk of central nervous system side effects such as extrapyramidal symptoms.
Well-Tolerated: Itopride is generally well-tolerated, with most adverse effects being mild and transient, including diarrhea, headache, abdominal pain, and nausea.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.4 | 0.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.4 | |
| Allergies | 0.4 | 0 | 0 |
| Allergy to milk products | 0.4 | -0.4 | |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.7 | 0.6 | 0.17 |
| Ankylosing spondylitis | 0.2 | 0.2 | |
| Anorexia Nervosa | 0.4 | 0.4 | |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Atrial fibrillation | 0.4 | 0.7 | -0.75 |
| Autism | 0.5 | 0.9 | -0.8 |
| Bipolar Disorder | 0.7 | 0.7 | |
| Carcinoma | 0.7 | 0.4 | 0.75 |
| Celiac Disease | 0.7 | -0.7 | |
| Chronic Fatigue Syndrome | 0.7 | -0.7 | |
| Chronic Kidney Disease | 0.4 | 0.3 | 0.33 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | |
| Cognitive Function | 0.4 | 0.4 | |
| Colorectal Cancer | 0.4 | 0.4 | |
| COVID-19 | 0.4 | 0 | 0 |
| Crohn's Disease | 0.9 | 0.4 | 1.25 |
| Depression | 0.9 | 0.4 | 1.25 |
| Endometriosis | 0.4 | 0.4 | |
| Epilepsy | 0.4 | -0.4 | |
| Fibromyalgia | 0.4 | 0 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.5 | -0.25 |
| gallstone disease (gsd) | 0.4 | 0.4 | |
| Graves' disease | 0.4 | 0.4 | |
| Hashimoto's thyroiditis | 0.3 | -0.3 | |
| Heart Failure | 0.4 | 0.4 | |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| hyperglycemia | 0.4 | -0.4 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.4 | 0 | 0 |
| IgA nephropathy (IgAN) | 0.4 | 0 | 0 |
| Inflammatory Bowel Disease | 0.4 | 0.8 | -1 |
| Intelligence | 0 | 0 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.4 | -0.4 | |
| ischemic stroke | 0.4 | 0.4 | |
| Liver Cirrhosis | 0.7 | 0.3 | 1.33 |
| Long COVID | 0.4 | 0.7 | -0.75 |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.1 | -0.1 | |
| Metabolic Syndrome | 1.3 | 0.7 | 0.86 |
| Mood Disorders | 0.9 | 0.4 | 1.25 |
| Multiple Sclerosis | 0.7 | 0.6 | 0.17 |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.4 | -0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0 | 0 | |
| Obesity | 0.9 | 0.4 | 1.25 |
| obsessive-compulsive disorder | 0.4 | 0 | 0 |
| Parkinson's Disease | 0.7 | 0 | 0 |
| Polycystic ovary syndrome | 0.6 | 0.3 | 1 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| Primary sclerosing cholangitis | 0.4 | 0.6 | -0.5 |
| Psoriasis | 0.6 | -0.6 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.7 | |
| Schizophrenia | 0.7 | 0.4 | 0.75 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.5 | 0.4 | 0.25 |
| Stress / posttraumatic stress disorder | 0.4 | 0.4 | 0 |
| Systemic Lupus Erythematosus | 0.7 | 0.7 | |
| Tic Disorder | 0 | 0 | |
| Type 1 Diabetes | 0.3 | 0.3 | |
| Type 2 Diabetes | 0.7 | 0.4 | 0.75 |
| Ulcerative colitis | 0.4 | 0.7 | -0.75 |
| Unhealthy Ageing | 0.3 | 0.4 | -0.33 |
| Vitiligo | 0.4 | 0.4 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
